NCT07316361 — Biogenea Pharmaceuticals neoantigen vaccine trial
GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer
Registry record
| Registry ID | NCT07316361 ↗ |
|---|---|
| Lead sponsor | Biogenea Pharmaceuticals Ltd. |
| Collaborators | — |
| Phase | Phase EARLY_PHASE1 |
| Status | Enrolling By Invitation |
| Indication | Endometrial Carcinoma, Endometrial Carcinoma Stage III |
| Enrollment | 40 participants (target) |
| Start date | 2026-02-02 |
| Primary completion | 2029-12-02 (est.) |
| Last registry update | 7 Jan 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT07316361), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT07316361?
NCT07316361 (GYNORYLAQ™-VLINIVAL™: Ψ-Guided Personalized Neoantigen Peptide Vaccine for High-Risk Endometrial Cancer) is registered on ClinicalTrials.gov as Phase EARLY_PHASE1, sponsored by Biogenea Pharmaceuticals Ltd..
Is NCT07316361 recruiting?
As of the 2026-01-07 registry update, NCT07316361 is listed as "Enrolling By Invitation". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT07316361?
The lead sponsor is Biogenea Pharmaceuticals Ltd..
What condition does NCT07316361 study?
The registered conditions are Endometrial Carcinoma, Endometrial Carcinoma Stage III. Primary completion is listed as 2029-12-02 (estimated).
Are results available for NCT07316361?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT07316361.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.